The Cardiovascular Effects of GLP-1 Receptor Agonists

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

(2010) Mads Halbirk et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

(2010) M. Arakawa et al.   DIABETES

Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy

(2010) Mary Parks et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes

(2009) T. Okerson et al.   AMERICAN JOURNAL OF HYPERTENSION

Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model

(2009) Kunio Hirata et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model

(2009) Jens Kristensen et al.   BMC Cardiovascular Disorders

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

(2009) M. H. Noyan-Ashraf et al.   DIABETES

Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study

(2009) R. A. Noel et al.   DIABETES CARE

Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury

(2009) Leo Timmers et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Exenatide Improves Hypertension in a Rat Model of the Metabolic Syndrome

(2009) Kevin D. Laugero et al.   Metabolic Syndrome and Related Disorders

Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation

(2009) Kristopher C. Dozier et al.   PEPTIDES

Impact of Individual and Cumulative Coronary Risk Factors on Coronary Flow Reserve Assessed by Dobutamine Stress Echocardiography

(2008) Saeed A.L. Ahmari et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effects of Intravenous Glucagon-Like Peptide-1 on Glucose Control and Hemodynamics After Coronary Artery Bypass Surgery in Patients With Type 2 Diabetes

(2008) Karsten Müssig et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans

(2008) Adil E. Bharucha et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP

(2008) Brian D. Green et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Microvascular degenerative complications are associated with increased aortic stiffness in type 2 diabetic patients

(2008) Claudia R.L. Cardoso et al.   ATHEROSCLEROSIS

Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats

(2008) S M Gardiner et al.   BRITISH JOURNAL OF PHARMACOLOGY

Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk

(2008) Tina Ken Schramm et al.   CIRCULATION

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION

Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat

(2008) Indu Poornima et al.   Circulation-Heart Failure

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

(2008) Ralph A. DeFronzo et al.   CURRENT MEDICAL RESEARCH AND OPINION

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

(2008) J.-P. Courrèges et al.   DIABETIC MEDICINE

Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients

(2008) K. Eeg-Olofsson et al.   DIABETOLOGIA

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart

(2007) David P. Sonne et al.   REGULATORY PEPTIDES